TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05092958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and urine samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and urine samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05825040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online guided transdiagnostic cognitive behavioural therapy
Description: The contents of guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. Customized guidance will be provided by coaches once a week based on participants' performance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-guided transdiagnostic cognitive behavioural therapy
Description: The contents of self-guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. No customized guidance will be provided to participants in the self-guided group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-guided mindfulness-based intervention
Description: The contents of online self-guided mindfulness-based intervention are developed by clinical psychologists and psychological well-being officers. The intervention consists of 6 modules. Contents include mindfulness and auto-pilot, react and respond, aversion, craving, equanimity, and 'suffering', thoughts and letting go, starting with loving kindness, and mindfulness in life.
Study: NCT06312215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed-system catheter
Description: Closed-system catheters was applied
Study: NCT05768906

Intervention type: OTHER
Intervention: observational
Description: Observation of disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians
Study: NCT05879588

Intervention type: OTHER
Group type: OTHER
Intervention: immediate orthodontic retainer delivery
Description: post orthodontic treatment patients will be given orthodontic retainer immediately after debonding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed orthodontic retainer delivery
Description: post orthodontic treatment patients will be given orthodontic retainer after 3 days of debonding
Study: NCT05603767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMT+ VR
Description: (RMT+ VR). The responsive music therapy session combined with virtual reality involves four stages: a) Background settings; b) VR video and music selection; c) Listening experience and VR; and e) Return to alert status. The therapist will help the patient to select the video to be used for the experience. Utilizing the application created by the research team, the patient will be provided with four possible scenarios. As for the music, patients are asked to choose music that relaxes them the most. Chosen music can be instrumental music (guitar, electric piano or violin) or sung music with harmonic accompaniment (piano or guitar). In both cases the music will be played live.
Study: NCT04977128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-KN035
Description: Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
Study: NCT06238154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen
Study: NCT05621811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naronapride
Description: Naronapride is a 5HT-4 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naronapride
Description: Naronapride is a 5HT-4 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naronapride
Description: Naronapride is a 5HT-4 agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05294887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: beta-adrenergic receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: beta-adrenergic receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: beta-adrenergic receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: beta-adrenergic receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: beta-adrenergic receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: beta-adrenergic receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06579872

Intervention type: OTHER
Intervention: plantar pressure
Description: foot pressure analysis, cardiopulmonary function, and mobility in patients with chronic respiratory diseases

Intervention type: OTHER
Intervention: plantar pressure
Description: foot pressure analysis, cardiopulmonary function, and mobility in patients with chronic respiratory diseases
Study: NCT05201807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1 (DT1)
Description: TEST Lens
Study: NCT05994430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End-of-life care awareness training in intensive care
Description: End-of-life care awareness training in intensive care
Study: NCT06387862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled
Description: Each patient will receive 12µg/kg of levosimendan by inhalation over 10 min. During 10h following inhaled dose, plasma concentrations will be measured.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous
Description: Each patient will receive 12µg/kg of levosimendan by intravenous (IV) administration over 10 min and at the same timepoints plasma samples will be measured
Study: NCT04781491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forest Therapy (Düppeler Forst - Berlin-Wannsee)
Description: Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna
Study: NCT04574336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: We anticipate that surgical treatment will include plate osteosynthesis (MIPO and ORIF), intramedullary nailing (antegrade and retrograde) and external fixation. Plate and nail types, screw configuration and surgical approaches will be decided by the surgeon. The procedure will be conducted or supervised by a senior consultant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatment
Description: Non-surgical treatment will include sugar tong, splint, plaster splints, hanging casts, or functional bracing as the Sarmiento brace and will be worn until a surgeon removes it. If the surgeon deems it appropriate, participants will be offered to undergo early secondary surgery with a surgical procedure of their choice. The participants will be recorded and the reason will be noted. We anticipate the surgical procedures will be similar to the previous mentioned and perhaps with the addition of bone graft.
Study: NCT06220110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing dextrose (1 capsule per day)
Study: NCT05096130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine Strategies
Description: LM addresses health risk factors in primary, secondary, and tertiary prevention of developing disease rather than limiting resources and medical expenditures on acute care and reacting to illness, injury, and disease.~The intervention will target the four pillars of the LM approach including physical activity, diet, stress, and sleep. Certified in LM strategies professionals will consult participants from the LM group in a biweekly base in order to improve their lifestyle habits.
Study: NCT05428644

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: massage therapy
Description: In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage and placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: massage therapy
Description: In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage and placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
Study: NCT05957406

Intervention type: DEVICE
Group type: OTHER
Intervention: Acumen HPI Smart Alerts and Smart Trends Software
Description: Device: Acumen HPI Smart Alerts and Smart Trends Software The Acumen HPI Smart Alerts and Smart Trends Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The Acumen HPI Smart Alerts and Smart Trends Software suite is enabled by the minimally invasive Acumen IQ sensor.

Intervention type: DEVICE
Group type: OTHER
Intervention: The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff
Description: Device: HemoSphere ClearSight Module and Pressure Controller, and adult Acumen IQ finger cuff
Study: NCT06208735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLIC-2201
Description: Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-2201 CAR-T cells. All treatments will be delivered intravenously.
Study: NCT05010824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene practices and behavioural intervention
Description: The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem. The second and third session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. Follow-up phone calls provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
Study: NCT05242939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video game
Description: The child will be allowed to play the game they want to play throughout the entire procedure, starting 5 minutes before the inhalation therapy. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
Study: NCT05421988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Description: EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Description: EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.
Study: NCT05550194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ValACYclovir 1000 MG
Description: Valacyclcovir is a targeted anti-viral for varicella zoster virus (VZV).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Vaccine indicated for prevention of herpes zoster
Study: NCT04894006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) Home Visit Intervention
Description: The on-site intervention will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions. The education of dementia caregiving skills will include (1) understanding about Alzheimer's and dementias, (2) appropriate communication skills with PWD, (3) daily activities for or with PWD together (e.g., puzzles, writing, reading, singing, taking a walk, etc), and (4) care resources including support groups, adult day centers, or other dementia related social services (legal and financial matters). For stress reduction techniques to be effective, the investigators have installed an app on the smartwatch to remind them to practice mindful breathing exercises two times a day and when needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group with WIoT Technology
Description: The caregivers randomly assigned to the AC group will be asked to wear the smartwatch during the day time and the smartring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, and sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months answering general questions from participants. CHW will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: The caregivers randomly assigned to UC group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. CHWs will contact them monthly for 6 months by phone asking general questions from participants. CHWs will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
Study: NCT04761887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cool Ropivacaine Block
Description: Ropivacaine is cooled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Room Temp Ropivacaine Block
Description: Room Temp Block
Study: NCT05881642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate and seminal-sparing Cystectomy
Description: Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Radical Cystoprostatectomy
Description: According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles
Study: NCT06592911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poppins Clinical
Description: Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
Study: NCT06615232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaginal washing cessation
Description: Participants will attend weekly small group (\~10 women per group) sessions that are structured using the transtheoretical model of behavioral change to promote vaginal washing cessation.
Study: NCT06610760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Subjects will be instructed to take one capsule (250mg) of ursodeoxycholic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be instructed to take one capsule (250mg) of placebo three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
Study: NCT04695106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate
Description: Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
Study: NCT05242939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watching cartoons
Description: The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
Study: NCT05477888

Intervention type: OTHER
Intervention: Questionnaires set
Description: Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,the Penn State Electronic Cigarette Dependence Index (PS-ECDI ).